|
1
|
Søreide K, Sandvik OM, Søreide JA, Giljaca
V, Jureckova A and Bulusu VR: Global epidemiology of
gastrointestinal stromal tumours (GIST): A systematic review of
population-based cohort studies. Cancer Epidemiol. 40:39–46. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miettinen M, Sobin LH and Lasota J:
Gastrointestinal stromal tumors of the stomach: A
clinicopathologic, immunohistochemical, and molecular genetic study
of 1765 cases with long-term follow-up. Am J Surg Pathol. 29:52–68.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Briggler AM, Graham RP, Westin GF, Folpe
AL, Jaroszewski DE, Okuno SH and Halfdanarson TR: Clinicopathologic
features and outcomes of gastrointestinal stromal tumors arising
from the esophagus and gastroesophageal junction. J Gastrointest
Oncol. 9:718–727. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Emile JF, Brahimi S, Coindre JM, Bringuier
PP, Monges G, Samb P, Doucet L, Hostein I, Landi B, Buisine MP, et
al: Frequencies of KIT and PDGFRA mutations in the MolecGIST
prospective population-based study differ from those of advanced
GISTs. Med Oncol. 29:1765–1772. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Agaimy A and Wünsch PH: Lymph node
metastasis in gastrointestinal stromal tumours (GIST) occurs
preferentially in young patients < or = 40 years: An overview
based on our case material and the literature. Langenbecks Arch
Surg. 394:375–381. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang L, Smyrk TC, Young WF Jr, Stratakis
CA and Carney JA: Gastric stromal tumors in Carney triad are
different clinically, pathologically, and behaviorally from
sporadic gastric gastrointestinal stromal tumors: Findings in 104
cases. Am J Surg Pathol. 34:53–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pink D, Schoeler D, Lindner T,
Thuss-Patience PC, Kretzschmar A, Knipp H, Vanhoefer U and
Reichardt P: Severe hypoglycemia caused by paraneoplastic
production of IGF-II in patients with advanced gastrointestinal
stromal tumors: A report of two cases. J Clin Oncol. 23:6809–6811.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maynard MA and Huang SA: Thyroid hormone
inactivation in gastrointestinal stromal tumors. N Engl J Med.
371:86–87. 2014.PubMed/NCBI
|
|
9
|
Duensing A, Medeiros F, McConarty B,
Joseph NE, Panigrahy D, Singer S, Fletcher CD, Demetri GD and
Fletcher JA: Mechanisms of oncogenic KIT signal transduction in
primary gastrointestinal stromal tumors (GISTs). Oncogene.
23:3999–4006. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ricci R: Syndromic gastrointestinal
stromal tumors. Hered Cancer Clin Pract. 14:152016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee NK, Lee JH, Kim WK, Yun S, Youn YH,
Park CH, Choi YY, Kim H and Lee SK: Promoter methylation of PCDH10
by HOTAIR regulates the progression of gastrointestinal stromal
tumors. Oncotarget. 7:75307–75318. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kupcinskas J: Small molecules in rare
tumors: Emerging role of microRNAs in GIST. Int J Mol Sci.
19:192018. View Article : Google Scholar
|
|
13
|
Demetri GD, Jeffers M and Reichardt PG:
Mutational analysis of plasma DNA from patients (pts) in the phase
III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine
kinase inhibitor (TKI)-refractory GIST: Correlating genotype with
clinical outcomes. Oncol Res Treat. 37:58. 2013.
|
|
14
|
Nilsson B, Bümming P, Meis-Kindblom JM,
Odén A, Dortok A, Gustavsson B, Sablinska K and Kindblom LG:
Gastrointestinal stromal tumors: The incidence, prevalence,
clinical course, and prognostication in the preimatinib mesylate
era-a population-based study in western Sweden. Cancer.
103:821–829. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Joensuu H, Vehtari A, Riihimäki J, Nishida
T, Steigen SE, Brabec P, Plank L, Nilsson B, Cirilli C, Braconi C,
et al: Risk of recurrence of gastrointestinal stromal tumour after
surgery: An analysis of pooled population-based cohorts. Lancet
Oncol. 13:265–274. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Janeway KA, Kim SY, Lodish M, Nosé V,
Rustin P, Gaal J, Dahia PL, Liegl B, Ball ER, Raygada M, et al: NIH
pediatric and wild-type GIST clinic: Defects in succinate
dehydrogenase in gastrointestinal stromal tumors lacking KIT and
PDGFRA mutations. Proc Natl Acad Sci USA. 108:314–318. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Broudy VC, Lin NL and Sabath DF: The fifth
immunoglobulin-like domain of the Kit receptor is required for
proteolytic cleavage from the cell surface. Cytokine. 15:188–195.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hanks SK, Quinn AM and Hunter T: The
protein kinase family: Conserved features and deduced phylogeny of
the catalytic domains. Science. 241:42–52. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lennartsson J and Rönnstrand L: Stem cell
factor receptor/c-Kit: From basic science to clinical implications.
Physiol Rev. 92:1619–1649. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roskoski R Jr: Signaling by Kit
protein-tyrosine kinase-the stem cell factor receptor. Biochem
Biophys Res Commun. 337:1–13. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lennartsson J, Blume-Jensen P, Hermanson
M, Pontén E, Carlberg M and Rönnstrand L: Phosphorylation of Shc by
Src family kinases is necessary for stem cell factor receptor/c-kit
mediated activation of the Ras/MAP kinase pathway and c-fos
induction. Oncogene. 18:5546–5553. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rotert JV, Leupold J, Hohenberger P, Nowak
K and Allgayer H: Src activity is increased in gastrointestinal
stromal tumors-analysis of associations with clinical and other
molecular tumor characteristics. J Surg Oncol. 109:597–605. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Serve H, Hsu YC and Besmer P: Tyrosine
residue 719 of the c-kit receptor is essential for binding of the
P85 subunit of phosphatidylinositol (PI) 3-kinase and for
c-kit-associated PI 3-kinase activity in COS-1 cells. J Biol Chem.
269:6026–6030. 1994.PubMed/NCBI
|
|
24
|
Sun J, Pedersen M and Rönnstrand L: Gab2
is involved in differential phosphoinositide 3-kinase signaling by
two splice forms of c-Kit. J Biol Chem. 283:27444–27451. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Deberry C, Mou S and Linnekin D: Stat1
associates with c-kit and is activated in response to stem cell
factor. Biochem J. 327:73–80. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brizzi MF, Blechman JM, Cavalloni G, Givol
D, Yarden Y and Pegoraro L: Protein kinase C-dependent release of a
functional whole extracellular domain of the mast cell growth
factor (MGF) receptor by MGF-dependent human myeloid cells.
Oncogene. 9:1583–1589. 1994.PubMed/NCBI
|
|
27
|
Heinrich MC, Patterson J, Beadling C, Wang
Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP,
Rubin B, et al: Genomic aberrations in cell cycle genes predict
progression of KIT-mutant gastrointestinal stromal tumors (GISTs).
Clin Sarcoma Res. 9:32019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
et al: Gain-of-function mutations of c-kit in human
gastrointestinal stromal tumors. Science. 279:577–580. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kinoshita K, Isozaki K, Hirota S, Nishida
T, Chen H, Nakahara M, Nagasawa Y, Ohashi A, Shinomura Y, Kitamura
Y and Matsuzawa Y: c-kit gene mutation at exon 17 or 13 is very
rare in sporadic gastrointestinal stromal tumors. J Gastroenterol
Hepatol. 18:147–151. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rubin BP, Singer S, Tsao C, Duensing A,
Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, et al: KIT
activation is a ubiquitous feature of gastrointestinal stromal
tumors. Cancer Res. 61:8118–8121. 2001.PubMed/NCBI
|
|
31
|
Heinrich MC, Corless CL, Demetri GD,
Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den
Abbeele AD, Druker BJ, et al: Kinase mutations and imatinib
response in patients with metastatic gastrointestinal stromal
tumor. J Clin Oncol. 21:4342–4349. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu CW, Lin S, Wang WL, Gao WB, Lv JY, Gao
JS, Zhang LY, Li Y, Wang L, Zhang YP and Tian YW: Analysis of
mutation of the c-Kit gene and PDGFRA in gastrointestinal stromal
tumors. Exp Ther Med. 10:1045–1051. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Martín J, Poveda A, Llombart-Bosch A,
Ramos R, López-Guerrero JA, García del Muro J, Maurel J, Calabuig
S, Gutierrez A, González de Sande JL, et al Spanish Group for
Sarcoma Research, : Deletions affecting codons 557–558 of the c-KIT
gene indicate a poor prognosis in patients with completely resected
gastrointestinal stromal tumors: A study by the Spanish Group for
Sarcoma Research (GEIS). J Clin Oncol. 23:6190–6198. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wardelmann E, Losen I, Hans V, Neidt I,
Speidel N, Bierhoff E, Heinicke T, Pietsch T, Büttner R and
Merkelbach-Bruse S: Deletion of Trp-557 and Lys-558 in the
juxtamembrane domain of the c-kit protooncogene is associated with
metastatic behavior of gastrointestinal stromal tumors. Int J
Cancer. 106:887–895. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Singer S, Rubin BP, Lux ML, Chen CJ,
Demetri GD, Fletcher CD and Fletcher JA: Prognostic value of KIT
mutation type, mitotic activity, and histologic subtype in
gastrointestinal stromal tumors. J Clin Oncol. 20:3898–3905. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wozniak A, Rutkowski P, Schöffski P,
Ray-Coquard I, Hostein I, Schildhaus HU, Le Cesne A, Bylina E,
Limon J, Blay JY, et al: Tumor genotype is an independent
prognostic factor in primary gastrointestinal stromal tumors of
gastric origin: A European Multicenter Analysis based on
ConticaGIST. Clin Cancer Res. 20:6105–6116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Quek R, Farid M, Kanjanapan Y, Lim C, Tan
IB, Kesavan S, Lim TKH, Oon LL, Goh BK, Chan WH, et al: Prognostic
significance of KIT exon 11 deletion mutation in intermediate-risk
gastrointestinal stromal tumor. Asia Pac J Clin Oncol. 13:115–124.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Debiec-Rychter M, Dumez H, Judson I, Wasag
B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H,
et al: Use of c-KIT/PDGFRA mutational analysis to predict the
clinical response to imatinib in patients with advanced
gastrointestinal stromal tumours entered on phase I and II studies
of the EORTC soft tissue and bone sarcoma group. Eur J Cancer.
40:689–695. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Antonescu CR, Sommer G, Sarran L,
Tschernyavsky SJ, Riedel E, Woodruff JM, Robson M, Maki R, Brennan
MF, Ladanyi M, et al: Association of KIT exon 9 mutations with
nongastric primary site and aggressive behavior: KIT mutation
analysis and clinical correlates of 120 gastrointestinal stromal
tumors. Clin Cancer Res. 9:3329–3337. 2003.PubMed/NCBI
|
|
40
|
Wozniak A, Rutkowski P, Piskorz A,
Ciwoniuk M, Osuch C, Bylina E, Sygut J, Chosia M, Rys J, Urbanczyk
K, et al: Prognostic value of KIT/PDGFRA mutations in
gastrointestinal stromal tumours (GIST): Polish clinical GIST
registry experience. Ann Oncol. 23:353–360. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lasota J, Wozniak A, Sarlomo-Rikala M, Rys
J, Kordek R, Nassar A, Sobin LH and Miettinen M: Mutations in exons
9 and 13 of KIT gene are rare events in gastrointestinal stromal
tumors. A study of 200 cases. Am J Pathol. 157:1091–1095. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sakurai S, Oguni S, Hironaka M, Fukayama
M, Morinaga S and Saito K: Mutations in c-kit gene exons 9 and 13
in gastrointestinal stromal tumors among Japanese. Jpn J Cancer
Res. 92:494–498. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Künstlinger H, Huss S, Merkelbach-Bruse S,
Binot E, Kleine MA, Loeser H, Mittler J, Hartmann W, Hohenberger P,
Reichardt P, et al: Gastrointestinal stromal tumors with KIT exon 9
mutations: Update on genotype-phenotype correlation and validation
of a high-resolution melting assay for mutational testing. Am J
Surg Pathol. 37:1648–1659. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mulet-Margalef N and Garcia-Del-Muro X:
Sunitinib in the treatment of gastrointestinal stromal tumor:
Patient selection and perspectives. Onco Targets Ther. 9:7573–7582.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yeh CN, Chen TW, Tseng JH, Liu YY, Wang
SY, Tsai CY, Chiang KC, Hwang TL, Jan YY and Chen MF: Surgical
management in metastatic gastrointestinal stromal tumor (GIST)
patients after imatinib mesylate treatment. J Surg Oncol.
102:599–603. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gao J, Tian Y, Li J, Sun N, Yuan J and
Shen L: Secondary mutations of c-KIT contribute to acquired
resistance to imatinib and decrease efficacy of sunitinib in
Chinese patients with gastrointestinal stromal tumors. Med Oncol.
30:5222013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yeh CN, Chen MH, Chen YY, Yang CY, Yen CC,
Tzen CY, Chen LT and Chen JS: A phase II trial of regorafenib in
patients with metastatic and/or a unresectable gastrointestinal
stromal tumor harboring secondary mutations of exon 17. Oncotarget.
8:44121–44130. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mazzocca A, Napolitano A, Silletta M,
Spalato Ceruso M, Santini D, Tonini G and Vincenzi B: New frontiers
in the medical management of gastrointestinal stromal tumours. Ther
Adv Med Oncol. 11:17588359198419462019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lasota J, Corless CL, Heinrich MC,
Debiec-Rychter M, Sciot R, Wardelmann E, Merkelbach-Bruse S,
Schildhaus HU, Steigen SE, Stachura J, et al: Clinicopathologic
profile of gastrointestinal stromal tumors (GISTs) with primary KIT
exon 13 or exon 17 mutations: A multicenter study on 54 cases. Mod
Pathol. 21:476–484. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lux ML, Rubin BP, Biase TL, Chen CJ,
Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD and Fletcher
JA: KIT extracellular and kinase domain mutations in
gastrointestinal stromal tumors. Am J Pathol. 156:791–795. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ning ZQ, Li J and Arceci RJ: Activating
mutations of c-kit at codon 816 confer drug resistance in human
leukemia cells. Leuk Lymphoma. 41:513–522. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Nagata H, Worobec AS, Oh CK, Chowdhury BA,
Tannenbaum S, Suzuki Y and Metcalfe DD: Identification of a point
mutation in the catalytic domain of the protooncogene c-kit in
peripheral blood mononuclear cells of patients who have
mastocytosis with an associated hematologic disorder. Proc Natl
Acad Sci USA. 92:10560–10564. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tian Q, Frierson HF Jr, Krystal GW and
Moskaluk CA: Activating c-kit gene mutations in human germ cell
tumors. Am J Pathol. 154:1643–1647. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hongyo T, Li T, Syaifudin M, Baskar R,
Ikeda H, Kanakura Y, Aozasa K and Nomura T: Specific c-kit
mutations in sinonasal natural killer/T-cell lymphoma in China and
Japan. Cancer Res. 60:2345–2347. 2000.PubMed/NCBI
|
|
55
|
Sakuma Y, Sakurai S, Oguni S, Satoh M,
Hironaka M and Saito K: c-kit gene mutations in intracranial
germinomas. Cancer Sci. 95:716–720. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Heinrich MC, Corless CL, Duensing A,
McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A,
Town A, et al: PDGFRA activating mutations in gastrointestinal
stromal tumors. Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Joensuu H, Hohenberger P and Corless CL:
Gastrointestinal stromal tumour. Lancet. 382:973–983. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wardelmann E, Hrychyk A, Merkelbach-Bruse
S, Pauls K, Goldstein J, Hohenberger P, Losen I, Manegold C,
Büttner R and Pietsch T: Association of platelet-derived growth
factor receptor alpha mutations with gastric primary site and
epithelioid or mixed cell morphology in gastrointestinal stromal
tumors. J Mol Diagn. 6:197–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Debiec-Rychter M, Wasag B, Stul M, De
Wever I, Van Oosterom A, Hagemeijer A and Sciot R: Gastrointestinal
stromal tumours (GISTs) negative for KIT (CD117 antigen)
immunoreactivity. J Pathol. 202:430–438. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lasota J, Dansonka-Mieszkowska A, Sobin LH
and Miettinen M: A great majority of GISTs with PDGFRA mutations
represent gastric tumors of low or no malignant potential. Lab
Invest. 84:874–883. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Indio V, Astolfi A, Tarantino G, Urbini M,
Patterson J, Nannini M, Saponara M, Gatto L, Santini D, do Valle
IF, et al: Integrated molecular characterization of
gastrointestinal stromal tumors (GIST) harboring the rare D842V
mutation in PDGFRA gene. Int J Mol Sci. 19:E7322018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Heinrich M, von Mehren M, Jones RL, Bauer
S, Kang YK, Schöffski P, Eskens F, Serrano C, Cassier PA, Mir O, et
al: Avapritinib is highly active and well-tolerated in patients
(pts) with advanced GIST driven by diverse variety of oncogenic
mutations in KIT and PDGFRA. Presented at: 2018 CTOS Annual
Meeting; November 15, 2018 Rome, Italy (abstract 3027631).
https://www.blueprintmedicines.com/wp-content/uploads/2019/01/CTOS-Avapritinib-Update-Nov-2018.pdf
|
|
63
|
Medeiros F, Corless CL, Duensing A,
Hornick JL, Oliveira AM, Heinrich MC, Fletcher JA and Fletcher CD:
KIT-negative gastrointestinal stromal tumors: Proof of concept and
therapeutic implications. Am J Surg Pathol. 28:889–894. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lasota J and Miettinen M: KIT and PDGFRA
mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn
Pathol. 23:91–102. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Corless CL, Schroeder A, Griffith D, Town
A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J and
Heinrich MC: PDGFRA mutations in gastrointestinal stromal tumors:
Frequency, spectrum and in vitro sensitivity to imatinib. J Clin
Oncol. 23:5357–5364. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lasota J, Stachura J and Miettinen M:
GISTs with PDGFRA exon 14 mutations represent subset of clinically
favorable gastric tumors with epithelioid morphology. Lab Invest.
86:94–100. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Nishida T, Hirota S, Taniguchi M,
Hashimoto K, Isozaki K, Nakamura H, Kanakura Y, Tanaka T,
Takabayashi A, Matsuda H and Kitamura Y: Familial gastrointestinal
stromal tumours with germline mutation of the KIT gene. Nat Genet.
19:323–324. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
68
|
Beghini A, Tibiletti MG, Roversi G,
Chiaravalli AM, Serio G, Capella C and Larizza L: Germline mutation
in the juxtamembrane domain of the kit gene in a family with
gastrointestinal stromal tumors and urticaria pigmentosa. Cancer.
92:657–662. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lasota J and Miettinen M: A new familial
GIST identified. Am J Surg Pathol. 30:13422006. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Robson ME, Glogowski E, Sommer G,
Antonescu CR, Nafa K, Maki RG, Ellis N, Besmer P, Brennan M and
Offit K: Pleomorphic characteristics of a germ-line KIT mutation in
a large kindred with gastrointestinal stromal tumors,
hyperpigmentation, and dysphagia. Clin Cancer Res. 10:1250–1254.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Hirota S, Nishida T, Isozaki K, Taniguchi
M, Nishikawa K, Ohashi A, Takabayashi A, Obayashi T, Okuno T,
Kinoshita K, et al: Familial gastrointestinal stromal tumors
associated with dysphagia and novel type germline mutation of KIT
gene. Gastroenterology. 122:1493–1499. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hartmann K, Wardelmann E, Ma Y,
Merkelbach-Bruse S, Preussner LM, Woolery C, Baldus SE, Heinicke T,
Thiele J, Buettner R and Longley BJ: Novel germline mutation of KIT
associated with familial gastrointestinal stromal tumors and
mastocytosis. Gastroenterology. 129:1042–1046. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Chompret A, Kannengiesser C, Barrois M,
Terrier P, Dahan P, Tursz T, Lenoir GM and Bressac-De Paillerets B:
PDGFRA germline mutation in a family with multiple cases of
gastrointestinal stromal tumor. Gastroenterology. 126:318–321.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Astolfi A, Nannini M, Pantaleo MA, Di
Battista M, Heinrich MC, Santini D, Catena F, Corless CL, Maleddu
A, Saponara M, et al: A molecular portrait of gastrointestinal
stromal tumors: An integrative analysis of gene expression
profiling and high-resolution genomic copy number. Lab Invest.
90:1285–1294. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wada R, Arai H, Kure S, Peng WX and Naito
Z: ‘Wild type’ GIST: Clinicopathological features and clinical
practice. Pathol Int. 66:431–437. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Prakash S, Sarran L, Socci N, DeMatteo RP,
Eisenstat J, Greco AM, Maki RG, Wexler LH, LaQuaglia MP, Besmer P
and Antonescu CR: Gastrointestinal stromal tumors in children and
young adults: A clinicopathologic, molecular, and genomic study of
15 cases and review of the literature. J Pediatr Hematol Oncol.
27:179–187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Janeway KA, Liegl B, Harlow A, Le C,
Perez-Atayde A, Kozakewich H, Corless CL, Heinrich MC and Fletcher
JA: Pediatric KIT wild-type and platelet-derived growth factor
receptor alpha-wild-type gastrointestinal stromal tumors share KIT
activation but not mechanisms of genetic progression with adult
gastrointestinal stromal tumors. Cancer Res. 67:9084–9088. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Gill AJ, Lipton L, Taylor J, Benn DE,
Richardson AL, Frydenberg M, Shapiro J, Clifton-Bligh RJ, Chow CW
and Bogwitz M: Germline SDHC mutation presenting as recurrent SDH
deficient GIST and renal carcinoma. Pathology. 45:689–691. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Miettinen M, Killian JK, Wang ZF, Lasota
J, Lau C, Jones L, Walker R, Pineda M, Zhu YJ, Kim SY, et al:
Immunohistochemical loss of succinate dehydrogenase subunit A
(SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA
germline mutation. Am J Surg Pathol. 37:234–240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Barletta JA and Hornick JL: Succinate
dehydrogenase-deficient tumors: Diagnostic advances and clinical
implications. Adv Anat Pathol. 19:193–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Gill AJ: Succinate dehydrogenase (SDH) and
mitochondrial driven neoplasia. Pathology. 44:285–292. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Gaal J, Stratakis CA, Carney JA, Ball ER,
Korpershoek E, Lodish MB, Levy I, Xekouki P, van Nederveen FH, den
Bakker MA, et al: SDHB immunohistochemistry: A useful tool in the
diagnosis of Carney-Stratakis and Carney triad gastrointestinal
stromal tumors. Mod Pathol. 24:147–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Miettinen M, Wang ZF, Sarlomo-Rikala M,
Osuch C, Rutkowski P and Lasota J: Succinate
dehydrogenase-deficient GISTs: A clinicopathologic,
immunohistochemical, and molecular genetic study of 66 gastric
GISTs with predilection to young age. Am J Surg Pathol.
35:1712–1721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Carney JA, Sheps SG, Go VL and Gordon H:
The triad of gastric leiomyosarcoma, functioning extra-adrenal
paraganglioma and pulmonary chondroma. N Engl J Med. 296:1517–1518.
1977. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Boikos SA, Pappo AS, Killian JK, LaQuaglia
MP, Weldon CB, George S, Trent JC, von Mehren M, Wright JA,
Schiffman JD, et al: Molecular subtypes of KIT/PDGFRA wild-type
gastrointestinal stromal tumors: A report from the national
institutes of health gastrointestinal stromal tumor clinic. JAMA
Oncol. 2:922–928. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Carney JA and Stratakis CA: Familial
paraganglioma and gastric stromal sarcoma: A new syndrome distinct
from the Carney triad. Am J Med Genet. 108:132–139. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
McWhinney SR, Pasini B and Stratakis CA;
International Carney Triad and Carney-Stratakis Syndrome
Consortium, : Familial gastrointestinal stromal tumors and
germ-line mutations. N Engl J Med. 357:1054–1056. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Pasini B, McWhinney SR, Bei T, Matyakhina
L, Stergiopoulos S, Muchow M, Boikos SA, Ferrando B, Pacak K, Assie
G, et al: Clinical and molecular genetics of patients with the
Carney-Stratakis syndrome and germline mutations of the genes
coding for the succinate dehydrogenase subunits SDHB, SDHC, and
SDHD. Eur J Hum Genet. 16:79–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Chou A, Chen J, Clarkson A, Samra JS,
Clifton-Bligh RJ, Hugh TJ and Gill AJ: Succinate
dehydrogenase-deficient GISTs are characterized by IGF1R
overexpression. Mod Pathol. 25:1307–1313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
LeRoith D and Roberts CT Jr: The
insulin-like growth factor system and cancer. Cancer Lett.
195:127–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Covello KL and Simon MC: HIFs, hypoxia,
and vascular development. Curr Top Dev Biol. 62:37–54. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Pugh CW and Ratcliffe PJ: Regulation of
angiogenesis by hypoxia: Role of the HIF system. Nat Med.
9:677–684. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Lasota J, Wang Z, Kim SY, Helman L and
Miettinen M: Expression of the receptor for type I insulin-like
growth factor (IGF1R) in gastrointestinal stromal tumors: An
immunohistochemical study of 1078 cases with diagnostic and
therapeutic implications. Am J Surg Pathol. 37:114–119. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Wu Y, Cui K, Miyoshi K, Hennighausen L,
Green JE, Setser J, LeRoith D and Yakar S: Reduced circulating
insulin-like growth factor I levels delay the onset of chemically
and genetically induced mammary tumors. Cancer Res. 63:4384–4388.
2003.PubMed/NCBI
|
|
95
|
Gallagher EJ and LeRoith D: Minireview:
IGF, insulin, and cancer. Endocrinology. 152:2546–2551. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Gotlieb WH, Bruchim I, Gu J, Shi Y,
Camirand A, Blouin MJ, Zhao Y and Pollak MN: Insulin-like growth
factor receptor I targeting in epithelial ovarian cancer. Gynecol
Oncol. 100:389–396. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Sarfstein R, Maor S, Reizner N,
Abramovitch S and Werner H: Transcriptional regulation of the
insulin-like growth factor-I receptor gene in breast cancer. Mol
Cell Endocrinol. 252:241–246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wu JD, Haugk K, Woodke L, Nelson P,
Coleman I and Plymate SR: Interaction of IGF signaling and the
androgen receptor in prostate cancer progression. J Cell Biochem.
99:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Mahadevan D, Sutton GR, Arteta-Bulos R,
Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN,
Marshall J, et al: Phase 1b study of safety, tolerability and
efficacy of R1507, a monoclonal antibody to IGF-1R in combination
with multiple standard oncology regimens in patients with advanced
solid malignancies. Cancer Chemother Pharmacol. 73:467–473. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Miettinen M, Fetsch JF, Sobin LH and
Lasota J: Gastrointestinal stromal tumors in patients with
neurofibromatosis 1: A clinicopathologic and molecular genetic
study of 45 cases. Am J Surg Pathol. 30:90–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Ferner RE: Neurofibromatosis 1 and
neurofibromatosis 2: A twenty first century perspective. Lancet
Neurol. 6:340–351. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Maertens O, Prenen H, Debiec-Rychter M,
Wozniak A, Sciot R, Pauwels P, De Wever I, Vermeesch JR, de Raedt
T, De Paepe A, et al: Molecular pathogenesis of multiple
gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet.
15:1015–1023. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Andersson J, Sihto H, Meis-Kindblom JM,
Joensuu H, Nupponen N and Kindblom LG: NF1-associated
gastrointestinal stromal tumors have unique clinical, phenotypic,
and genotypic characteristics. Am J Surg Pathol. 29:1170–1176.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Mussi C, Schildhaus HU, Gronchi A,
Wardelmann E and Hohenberger P: Therapeutic consequences from
molecular biology for gastrointestinal stromal tumor patients
affected by neurofibromatosis type 1. Clin Cancer Res.
14:4550–4555. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Kalender M, Sevinc A, Tutar E, Sirikci A
and Camci C: Effect of sunitinib on metastatic gastrointestinal
stromal tumor in patients with neurofibromatosis type 1: A case
report. World J Gastroenterol. 13:2629–2632. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Cui Y and Guadagno TM: B-Raf (V600E)
signaling deregulates the mitotic spindle checkpoint through
stabilizing Mps1 levels in melanoma cells. Oncogene. 27:3122–3133.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Matos P, Oliveira C, Velho S, Gonçalves V,
da Costa LT, Moyer MP, Seruca R and Jordan P: B-Raf(V600E)
cooperates with alternative spliced Rac1b to sustain colorectal
cancer cell survival. Gastroenterology. 135:899–906. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Huss S, Pasternack H, Ihle MA,
Merkelbach-Bruse S, Heitkötter B, Hartmann W, Trautmann M,
Gevensleben H, Büttner R, Schildhaus HU and Wardelmann E:
Clinicopathological and molecular features of a large cohort of
gastrointestinal stromal tumors (GISTs) and review of the
literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare
events. Hum Pathol. 62:206–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Hostein I, Faur N, Primois C, Boury F,
Denard J, Emile JF, Bringuier PP, Scoazec JY and Coindre JM: BRAF
mutation status in gastrointestinal stromal tumors. Am J Clin
Pathol. 133:141–148. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Rossi S, Gasparotto D, Miceli R,
Toffolatti L, Gallina G, Scaramel E, Marzotto A, Boscato E,
Messerini L, Bearzi I, et al: KIT, PDGFRA, and BRAF mutational
spectrum impacts on the natural history of imatinib-naive localized
GIST: A population-based study. Am J Surg Pathol. 39:922–930. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Simanshu DK, Nissley DV and McCormick F:
RAS Proteins and their regulators in human disease. Cell.
170:17–33. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Miranda C, Nucifora M, Molinari F, Conca
E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S,
Pierotti MA, et al: KRAS and BRAF mutations predict primary
resistance to imatinib in gastrointestinal stromal tumors. Clin
Cancer Res. 18:1769–1776. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Pantaleo MA, Nannini M, Corless CL and
Heinrich MC: Quadruple wild-type (WT) GIST: Defining the subset of
GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling
pathways. Cancer Med. 4:101–103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Nannini M, Astolfi A, Urbini M, Indio V,
Santini D, Heinrich MC, Corless CL, Ceccarelli C, Saponara M,
Mandrioli A, et al: Integrated genomic study of quadruple-WT GIST
(KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer.
14:6852014. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Brenca M, Rossi S, Polano M, Gasparotto D,
Zanatta L, Racanelli D, Valori L, Lamon S, Dei Tos AP and Maestro
R: Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion
involved in GIST. J Pathol. 238:543–549. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Shi Y, Gao X, Hu Q, Li X, Xu J, Lu S, Liu
Y, Xu C, Jiang D, Lin J, et al: PIK3C2A is a gene-specific target
of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal
stromal tumor. Lab Invest. 96:652–660. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Belinsky MG, Rink L, Cai KQ, Capuzzi SJ,
Hoang Y, Chien J, Godwin AK and von Mehren M: Somatic loss of
function mutations in neurofibromin 1 and MYC associated factor X
genes identified by exome-wide sequencing in a wild-type GIST case.
BMC Cancer. 15:8872015. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Pantaleo MA, Urbini M, Indio V, Ravegnini
G, Nannini M, De Luca M, Tarantino G, Angelini S, Gronchi A,
Vincenzi B, et al: Genome-wide analysis identifies MEN1 and MAX
mutations and a neuroendocrine-like molecular heterogeneity in
quadruple WT GIST. Mol Cancer Res. 15:553–562. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Henze J, Mühlenberg T, Simon S, Grabellus
F, Rubin B, Taeger G, Schuler M, Treckmann J, Debiec-Rychter M,
Taguchi T, et al: p53 modulation as a therapeutic strategy in
gastrointestinal stromal tumors. PLoS One. 7:e377762012. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Stewart CM and Tsui DWY: Circulating
cell-free DNA for non-invasive cancer management. Cancer Genet.
228-229:169–179. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Wan JCM, Massie C, Garcia-Corbacho J,
Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R and Rosenfeld N:
Liquid biopsies come of age: Towards implementation of circulating
tumour DNA. Nat Rev Cancer. 17:223–238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Kidess E and Jeffrey SS: Circulating tumor
cells versus tumor-derived cell-free DNA: Rivals or partners in
cancer care in the era of single-cell analysis? Genome Med.
5:702013. View
Article : Google Scholar : PubMed/NCBI
|
|
124
|
Fiala C and Diamandis EP: Utility of
circulating tumor DNA in cancer diagnostics with emphasis on early
detection. BMC Med. 16:1662018. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Elazezy M and Joosse SA: Techniques of
using circulating tumor DNA as a liquid biopsy component in cancer
management. Comput Struct Biotechnol J. 16:370–378. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Maier J, Lange T, Kerle I, Specht K,
Bruegel M, Wickenhauser C, Jost P, Niederwieser D, Peschel C,
Duyster J and von Bubnoff N: Detection of mutant free circulating
tumor DNA in the plasma of patients with gastrointestinal stromal
tumor harboring activating mutations of CKIT or PDGFRA. Clin Cancer
Res. 19:4854–4867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Namløs HM, Boye K, Mishkin SJ, Barøy T,
Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA,
Myklebost O and Meza-Zepeda LA: Noninvasive detection of ctDNA
reveals intratumor heterogeneity and is associated with tumor
burden in gastrointestinal stromal tumor. Mol Cancer Ther.
17:2473–2480. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Jilg S, Rassner M, Maier J, Waldeck S,
Kehl V, Follo M, Philipp U, Sauter A, Specht K, Mitschke J, et al:
Circulating cKIT and PDGFRA DNA indicates disease activity in
gastrointestinal stromal tumor (GIST). Int J Cancer. 145:2292–2303.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Steponaitiene R, Kupcinskas J, Langner C,
Balaguer F, Venclauskas L, Pauzas H, Tamelis A, Skieceviciene J,
Kupcinskas L, Malfertheiner P and Link A: Epigenetic silencing of
miR-137 is a frequent event in gastric carcinogenesis. Mol
Carcinog. 55:376–386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Balaguer F, Link A, Lozano JJ, Cuatrecasas
M, Nagasaka T, Boland CR and Goel A: Epigenetic silencing of
miR-137 is an early event in colorectal carcinogenesis. Cancer Res.
70:6609–6618. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Rizzato C, Campa D, Talar-Wojnarowska R,
Halloran C, Kupcinskas J, Butturini G, Mohelníková-Duchoňová B,
Sperti C, Tjaden C, Ghaneh P, et al: Association of genetic
polymorphisms with survival of pancreatic ductal adenocarcinoma
patients. Carcinogenesis. 37:957–964. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Catanzaro G, Sabato C, Russo M, Rosa A,
Abballe L, Besharat ZM, Po A, Miele E, Bellavia D, Chiacchiarini M,
et al: Loss of miR-107, miR-181c and miR-29a-3p promote activation
of Notch2 signaling in pediatric high-grade gliomas (pHGGs). Int J
Mol Sci. 18:E27422017. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Ihle MA, Trautmann M, Kuenstlinger H, Huss
S, Heydt C, Fassunke J, Wardelmann E, Bauer S, Schildhaus HU,
Buettner R and Merkelbach-Bruse S: miRNA-221 and miRNA-222 induce
apoptosis via the KIT/AKT signalling pathway in gastrointestinal
stromal tumours. Mol Oncol. 9:1421–1433. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Gits CM, van Kuijk PF, Jonkers MB, Boersma
AW, van Ijcken WF, Wozniak A, Sciot R, Rutkowski P, Schöffski P,
Taguchi T, et al: MiR-17-92 and miR-221/222 cluster members target
KIT and ETV1 in human gastrointestinal stromal tumours. Br J
Cancer. 109:1625–1635. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Cao CL, Niu HJ, Kang SP, Cong CL and Kang
SR: miRNA-21 sensitizes gastrointestinal stromal tumors (GISTs)
cells to imatinib via targeting B-cell lymphoma 2 (Bcl-2). Eur Rev
Med Pharmacol Sci. 20:3574–3581. 2016.PubMed/NCBI
|
|
137
|
Yamamoto H, Kohashi K, Fujita A and Oda Y:
Fascin-1 overexpression and miR-133b downregulation in the
progression of gastrointestinal stromal tumor. Mod Pathol.
26:563–571. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Liu S, Cui J, Liao G, Zhang Y, Ye K, Lu T,
Qi J and Wan G: MiR-137 regulates epithelial-mesenchymal transition
in gastrointestinal stromal tumor. Tumour Biol. 35:9131–9138. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Lu HJ, Yan J, Jin PY, Zheng GH, Qin SM, Wu
DM, Lu J and Zheng YL: MicroRNA-152 inhibits tumor cell growth
while inducing apoptosis via the transcriptional repression of
cathepsin L in gastrointestinal stromal tumor. Cancer Biomark.
21:711–722. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Fan R, Zhong J, Zheng S, Wang Z, Xu Y, Li
S, Zhou J and Yuan F: MicroRNA-218 inhibits gastrointestinal
stromal tumor cell and invasion by targeting KIT. Tumour Biol.
35:4209–4217. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Yun S, Kim WK, Kwon Y, Jang M, Bauer S and
Kim H: Survivin is a novel transcription regulator of KIT and is
downregulated by miRNA-494 in gastrointestinal stromal tumors. Int
J Cancer. 142:2080–2093. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Huang WK, Akçakaya P, Gangaev A, Lee L,
Zeljic K, Hajeri P, Berglund E, Ghaderi M, Åhlén J, Bränström R, et
al: miR-125a-5p regulation increases phosphorylation of FAK that
contributes to imatinib resistance in gastrointestinal stromal
tumors. Exp Cell Res. 371:287–296. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Niinuma T, Suzuki H, Nojima M, Nosho K,
Yamamoto H, Takamaru H, Yamamoto E, Maruyama R, Nobuoka T, Miyazaki
Y, et al: Upregulation of miR-196a and HOTAIR drive malignant
character in gastrointestinal stromal tumors. Cancer Res.
72:1126–1136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Akçakaya P, Caramuta S, Åhlen J, Ghaderi
M, Berglund E, Östman A, Bränström R, Larsson C and Lui WO:
microRNA expression signatures of gastrointestinal stromal tumours:
Associations with imatinib resistance and patient outcome. Br J
Cancer. 111:2091–2102. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Juzėnas S, Saltenienė V, Kupcinskas J,
Link A, Kiudelis G, Jonaitis L, Jarmalaite S, Kupcinskas L,
Malfertheiner P and Skieceviciene J: Analysis of deregulated
microRNAs and their target genes in gastric cancer. PLoS One.
10:e01323272015. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
ElSharawy A, Röder C, Becker T, Habermann
JK, Schreiber S, Rosenstiel P and Kalthoff H: Concentration of
circulating miRNA-containing particles in serum enhances miRNA
detection and reflects CRC tissue-related deregulations.
Oncotarget. 7:75353–75365. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Alemar B, Izetti P, Gregório C, Macedo GS,
Castro MA, Osvaldt AB, Matte U and Ashton-Prolla P: miRNA-21 and
miRNA-34a Are potential minimally invasive biomarkers for the
diagnosis of pancreatic ductal adenocarcinoma. Pancreas. 45:84–92.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Kou Y, Yang R and Wang Q: Serum
miR-518e-5p is a potential biomarker for secondary
imatinib-resistant gastrointestinal stromal tumor. J Biosci.
43:1015–1023. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Schmitt AM and Chang HY: Long noncoding
RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Bure I, Geer S, Knopf J, Roas M, Henze S,
Ströbel P, Agaimy A, Wiemann S, Hoheisel JD, Hartmann A, et al:
Long noncoding RNA HOTAIR is upregulated in an aggressive subgroup
of gastrointestinal stromal tumors (GIST) and mediates the
establishment of gene-specific DNA methylation patterns. Genes
Chromosomes Cancer. 57:584–597. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Yan J, Chen D, Chen X, Sun X, Dong Q, Hu
C, Zhou F and Chen W: Downregulation of lncRNA CCDC26 contributes
to imatinib resistance in human gastrointestinal stromal tumors
through IGF-1R upregulation. Braz J Med Biol Res. 52:e83992019.
View Article : Google Scholar : PubMed/NCBI
|
